Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham Collins, Kerry J. Savage, Marek Trneny, Kazunobu Kato, Benedetto Farsaci, Susan M. Parker, Scott Rodig, Margaretha G M Roemer, Azra H. LigonAndreas Engert

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences